Skip to main content

Table 2 hrHPV prevalence, by self-reported HIV infection status, among women from two rural districts of Uganda participating in a community-based study of cervical cancer screening

From: Prevalence, correlates, and predictive value of high-risk human papillomavirus mRNA detection in a community-based cervical cancer screening program in western Uganda

hrHPV Type Detected HIV-infectedc Participants (N = 160)
% (95% CI)
HIV-uninfected Participants (N = 1507) % (95% CI) HIV-untested Participants (N = 225) % (95% CI) All Participants (N = 1892) % (95% CI)
Any hrHPV 40% (32 to 48%) 19% (17 to 21%) 17% (12 to 22%) 21% (19 to 23%)
At least one of HPV-16, 18 and 45a 11% (6.3 to 16%) 4.0% (3.1 to 5.2%) 4.0% (1.8 to 7.5%) 4.6% (3.7 to 5.6%)
HPV-16a, b 4.4% (1.8 to 8.8%) 2.7% (1.9 to 3.6%) 2.2% (0.7 to 5.1%) 2.7% (2.1 to 3.6%)
HPV-18 and/or 45a, b 6.9% (3.5 to 12%) 1.5% (0.9 to 2.2% 1.8% (0.5 to 4.5%) 1.8% (1.3 to 2.6%)
At least one of HPV-31, 33, 35, 39, 51, 52, 56, 58, 59, 66 and 68 but without 16, 18 and 45 29% (22 to 36%) 15% (13 to 17%) 13% (8.8 to 18%) 16% (14 to 18%)
  1. amay also include HPV-31, 33, 35, 39, 51, 52, 56, 58, 59, 66 and 68
  2. bIncludes 2 patients who were positive for HPV-16 and HPV-18/45
  3. cHIV infection status ascertained by self-report